Vaxart's stock price is tumbling due to the announcement of a public offering of common stock. This dilutes the value of existing shares, leading to a decrease in stock price. The funds raised will be used for clinical development and manufacturing, which may have a positive impact in the long term, but the short-term impact is negative.